Smooth the lines. Keep the experiences that made them

BOTOX® Cosmetic from Eden Spa and Laser is the first and only treatment FDA-approved to temporarily make moderate to severe frown lines, crow's feet and forehead lines look better in adults. So you look like you, only with less noticeable facial lines.

Eden Spa and Laser offers a quick 10-minute treatment with minimal downtime. You may begin to notice results within 24 to 48 hours, with results lasting up to 4 months for moderate to severe frown lines.

Learn why there’s only one BOTOX Cosmetic and find out how it works. Then get answers to your questions to see if it's right for you and learn more about the history that has made BOTOX® Cosmetic the #1 selling treatment of its kind in the world.*

*Data collected through May 2016

Why BOTOX® Cosmetic Is More Than Skin Deep.

A combination of factors can cause facial lines. It’s not just about the cellular changes that may occur, or reduction of collagen, or damage caused by free radicals from the sun and the environment.

Repeated muscle contractions from frowning, squinting, or raising eyebrows cause skin to furrow and fold, gradually resulting in the formation of facial lines. BOTOX® Cosmetic is a quick 10-minute treatment that works beneath the surface and temporarily reduces the underlying muscle activity that causes moderate to severe frown lines, crow’s feet and forehead lines in adults – to help them look better.

Alexandra

Moderate to Severe Frown Lines, Crow's Feet, and Forehead Lines

Brooke

Moderate to Severe Frown Lines and Crow's Feet

LeAnn

Moderate to Severe Frown Lines, Crow's Feet, and Forehead Lines

Melba

Moderate to Severe Frown Lines and Crow's Feet

Marianne

Moderate to Severe Frown Lines and Crow's Feet

Nancy

Moderate to Severe Frown Lines, Crow's Feet, and Forehead Lines

Forehead Lines

Actual patient. Results may vary.
Photos taken at maximum eyebrow elevation before and 7 days after treatment with BOTOX® Cosmetic. In 2 clinical studies of healthy adults, 61% and 46% had a ≥ 2-grade improvement in their forehead lines at day 30.2

Crow’s Feet

Actual patient. Results may vary.
Photos taken at full smile before and 7 days after treatment with BOTOX® Cosmetic. In 2 clinical studies, 26.1% and 20.3% of adults had a ≥ 2-grade improvement at day 30. In one of these studies, 67.9% had mild or no crow’s feet lines at day 30 after treatment.2

Frown Lines

Actual patient. Results may vary.
Photos taken at maximum frown before and 7 days after treatment with BOTOX® Cosmetic. In clinical studies, physicians assessed 74% of adults had significant improvement at day 7; and 80% had significant improvement at day 30.2

1 Allergan Data on File, BOTOX Cosmetic 2015 WW Leader in Cosmetic NM Market, 2015.

2 BOTOX® Cosmetic Prescribing Information, 2017.

The Truth About BOTOX® Cosmetic

BOTOX® Cosmetic is an iconic brand. It’s been approved for use in 96 countries. But find out the truth behind common misconceptions, and you’ll get to know BOTOX® Cosmetic even better.

Schedule a Consultation


    [gap size="100px"]

    Start Saving with
    Brilliant Distinctions®

    The rewards program that helps you save on LATISSE® and select Allergan products and services.

    [button type="real" shape="pill" size="Large" href="https://www.brilliantdistinctionsprogram.com/" block="true" title="Register Now"]Register Now[/button]

    BOTOX® Cosmetic (onabotulinumtoxinA) Important Information
    Indications
    BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
    - moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
    - moderate to severe lateral canthal lines associated with orbicularis oculi activity
    - moderate to severe forehead lines associated with frontalis activity
    IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
    WARNING: DISTANT SPREAD OF TOXIN EFFECT
    Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the
    area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized
    muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These
    symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening
    and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but
    symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an
    underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children,
    and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical
    dystonia and spasticity and at lower doses.

    CONTRAINDICATIONS
    BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known
    hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.
    WARNINGS AND PRECAUTIONS
    Lack of Interchangeability between Botulinum Toxin Products
    The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable
    with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be
    compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.
    Spread of Toxin Effect
    Please refer to Boxed Warning for Distant Spread of Toxin Effect.
    No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic
    at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar
    lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous
    treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported.
    Serious Adverse Reactions With Unapproved Use
    Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions
    associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In
    these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the
    administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing
    dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk
    for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved
    uses have not been established.
    Hypersensitivity Reactions
    Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness,
    urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued
    and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine
    was used as the diluent and, consequently, the causal agent cannot be reliably determined.

    Cardiovascular System
    There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including
    arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing
    cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

    BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY INFORMATION (continued)
    WARNINGS AND PRECAUTIONS (continued)
    Increased Risk of Clinically Significant Effects with Pre-existing Neuromuscular Disorders
    Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders
    (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with
    neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness,
    diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see
    Warnings and Precautions).
    Dysphagia and Breathing Difficulties
    Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with
    pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a
    consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that
    control swallowing or breathing (see Boxed Warning).
    Pre-existing Conditions at the Injection Site
    Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection
    site(s) or when excessive weakness or atrophy is present in the target muscle(s).
    Human Albumin and Transmission of Viral Diseases
    This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing
    processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
    There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of
    transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever
    been identified for licensed albumin or albumin contained in other licensed products.
    ADVERSE REACTIONS
    The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for glabellar lines was eyelid
    ptosis (3%).
    The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid
    edema (1%).
    The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines
    were headache (9%), brow ptosis (2%) and eyelid ptosis (2%).

    DRUG INTERACTIONS
    Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission
    (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of
    anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.
    The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is
    unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the
    resolution of the effects of a previously administered botulinum toxin.
    Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of
    BOTOX® Cosmetic.
    USE IN SPECIFIC POPULATIONS
    There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of
    BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the
    effects on the breastfed child, or the effects on milk production.

    Approved Uses
    BOTOX® Cosmetic (onabotulinumtoxinA) is a prescription medicine that is injected into muscles and used to temporarily
    improve the look of moderate to severe forehead lines, crow’s feet lines, and frown lines between the eyebrows in adults.
    IMPORTANT SAFETY INFORMATION
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any
    of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss
    of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for
    several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious
    symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids,
    hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and
    trouble swallowing.
    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the
    recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks
    of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
    Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma
    symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you
    become dizzy or faint.
    Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for
    ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc ® (rimabotulinumtoxinB), Dysport ®
    (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.